| A genome-wide association study identifies multiple susceptibility loci for chronic lymphocytic leukemia HE Speedy, MC Di Bernardo, GP Sava, MJS Dyer, A Holroyd, Y Wang, ... Nature genetics 46 (1), 56-60, 2014 | 233 | 2014 |
| CDK7 inhibitors as anticancer drugs GP Sava, H Fan, RC Coombes, L Buluwela, S Ali Cancer and Metastasis Reviews 39, 805-823, 2020 | 147 | 2020 |
| ICEC0942, an orally bioavailable selective inhibitor of CDK7 for cancer treatment H Patel, M Periyasamy, GP Sava, A Bondke, BW Slafer, SHB Kroll, ... Molecular cancer therapeutics 17 (6), 1156-1166, 2018 | 123 | 2018 |
| Genome-wide association analysis implicates dysregulation of immunity genes in chronic lymphocytic leukaemia PJ Law, SI Berndt, HE Speedy, NJ Camp, GP Sava, CF Skibola, ... Nature communications 8 (1), 14175, 2017 | 105 | 2017 |
| Genetic predisposition to chronic lymphocytic leukemia is mediated by a BMF super-enhancer polymorphism R Kandaswamy, GP Sava, HE Speedy, S Beà, JI Martín-Subero, JB Studd, ... Cell reports 16 (8), 2061-2067, 2016 | 68 | 2016 |
| Common variation at 12q24. 13 (OAS3) influences chronic lymphocytic leukemia risk GP Sava, HE Speedy, MC Di Bernardo, MJS Dyer, A Holroyd, NJ Sunter, ... Leukemia 29 (3), 748-751, 2015 | 29 | 2015 |
| ABC-transporter upregulation mediates resistance to the CDK7 inhibitors THZ1 and ICEC0942 GP Sava, H Fan, RA Fisher, S Lusvarghi, S Pancholi, SV Ambudkar, ... Oncogene 39 (3), 651-663, 2020 | 27 | 2020 |
| Inherited susceptibility to CLL HE Speedy, G Sava, RS Houlston Advances in Chronic Lymphocytic Leukemia, 293-308, 2013 | 19 | 2013 |
| Candidate gene association studies and risk of chronic lymphocytic leukemia: a systematic review and meta-analysis GP Sava, HE Speedy, RS Houlston Leukemia & Lymphoma 55 (1), 160-167, 2014 | 16 | 2014 |
| Active growth signaling promotes senescence and cancer cell sensitivity to CDK7 inhibition GA Wilson, K Vuina, G Sava, C Huard, L Meneguello, ... Molecular cell 83 (22), 4078-4092. e6, 2023 | 13 | 2023 |
| Active growth signalling promotes cancer cell sensitivity to the CDK7 inhibitor ICEC0942 GA Wilson, G Sava, K Vuina, C Huard, L Meneguello, ... BioRxiv, 2021.09. 10.459733, 2021 | 10 | 2021 |
| rs2072135, a low‐penetrance variant for chronic lymphocytic leukaemia? GP Sava, HE Speedy, MC Di Bernardo, S Deaglio, L Karabon, I Frydecka, ... British journal of haematology 162 (2), 221-228, 2013 | 1 | 2013 |
| Defining modulators of response to samuraciclib, a CDK7 inhibitor for breast cancer K Jurgaityte, G Sava, CF Lai, H Fan, V Nguyen, L Buluwela, S Ali Cancer Research 83 (7_Supplement), 1557-1557, 2023 | | 2023 |
| Developing themes in targeted therapies for hormone receptor–positive breast cancer GP Sava, S Ali Current Opinion in Endocrine and Metabolic Research 15, 15-23, 2020 | | 2020 |
| Abstract P1-10-05: ICEC0942, a new oral selective inhibitor of the cell cycle and transcriptional regulator CDK7 for the treatment of estrogen receptor positive and negative … S Ali, H Patel, M Periyasamy, G Sava, A Bondke, BW Slafer, SHB Kroll, ... Cancer Research 78 (4_Supplement), P1-10-05-P1-10-05, 2018 | | 2018 |
